NAII

Business Context and Reporting Period

Company: Natural Alternatives International, Inc. (NAII)

Filing Type: Form 10-Q (Quarterly Report)

Reporting Period: Three months ended September 30, 2025 (Fiscal Q1 2026)

Business Overview: NAII operates in two primary segments: private-label contract manufacturing for nutritional supplements and patent/trademark licensing for beta-alanine ingredients (CarnoSyn®, SR CarnoSyn®, TriBsyn™). The company is a smaller reporting company and non-accelerated filer.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 14% year-over-year, driven by an 18% increase in private-label contract manufacturing sales due to higher orders from existing customers and new customer shipments.
• Licensing Decline: Patent and trademark licensing revenue decreased 34% to $1.67 million, primarily due to lower raw material sales, partially offset by new TriBsyn™ product sales and royalties.
• Margin Expansion: Gross margin improved significantly from 6.8% to 11.7%, attributed to better factory capacity utilization, favorable product mix, and lower volume rebates.
• Profitability: The company returned to operating profitability ($0.28M) compared to an operating loss of $1.84M in the prior year, though a net loss persisted due to interest expense and foreign exchange losses.
• Working Capital: Accounts receivable increased by $4.27 million and inventory increased by $5.78 million, consuming significant operating cash.

Guidance, Outlook, and Risks

Management Commentary and Outlook

• Profitability Forecast: Management anticipates a net loss for the first half of fiscal 2026 but expects net income for the second half and the full fiscal year 2026.
• Customer Concentration: The largest customer represented 38% of net sales in Q1 2026. Management expects annualized concentration for the largest customer to decrease in fiscal 2026.
• Product Strategy: Continued focus on commercializing TriBsyn™ and SR CarnoSyn™ to penetrate Wellness and Healthy Aging markets.

Risks and Contingencies

• Covenant Compliance: The company was not in compliance with net loss and fixed charge coverage ratio covenants for Q1 2026. Management anticipates non-compliance in Q2 2026 due to litigation expenses and valuation allowances. Negotiations for a credit agreement revision are ongoing with no assurance of success.
• Litigation: A tentative settlement of up to $1.25 million plus legal fees has been reached regarding a former employee class action lawsuit; court approval is pending.
• Tax Credits: The IRS denied a portion of the Employee Retention Tax Credit (ERTC) claim for Q3 2021. The company is contesting this denial.
• Geopolitical and Trade: Risks include potential tariffs on beta-alanine and raw materials, as well as supply chain disruptions from conflicts in the Middle East and Eastern Europe.

Investor Verification Checklist

• Credit Facility Status: Verify the outcome of negotiations with Wells Fargo regarding covenant waivers or amendments, as failure to secure terms could trigger a default.
• Cash Burn Rate: Monitor operating cash flow usage, which was $4.02 million in Q1, against the $7.74 million cash balance and $7.5 million available borrowing capacity.
• Customer Concentration: Assess the stability of the top customer (38% of sales) and the timeline for diversification.
• Inventory Levels: Review the $30.65 million inventory balance (up $5.8M from prior quarter) to ensure it aligns with demand forecasts and does not require future write-downs.
• Dividend Repatriation: Confirm the impact of the $3.1 million dividend paid by the Swiss subsidiary (NAIE) to the U.S. parent on consolidated liquidity and tax obligations.